Identification of new gonadotrophin-releasing hormone partial agonists

Journal of Endocrinology

Volumn 189, Issue 3, 2006, Pages 509-517

  Leaños Miranda, Alfredo ^a,b   Ulloa Aguirre, Alfredo ^a,b   Cervini, Laura A ^c   Janovick, Jo Ann ^a   Rivier, Jean ^c   Conn, P Michael ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Hospital Luis Castelazo Ayala   (Mexico)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GONADOTROPIN; INOSITOL PHOSPHATE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BINDING, COMPETITIVE; BUSERELIN; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INOSITOL PHOSPHATES; PROTEIN BINDING; RATS; RECEPTORS, LHRH; TRANSFECTION;

EID: 33745225884     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06724     Document Type: Article

References (50)

1. Belchetz PE, Plant TM, Nakai Y, Keogh EJ & Knobil E 1978 Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 202 631-633.
2. Bolonna AA & Kerwin RW 2005 Partial agonism and schizophrenia. British Journal of Psychiatry 186 7-10.
3. Brink CB, Harvey BH, Bodenstein J, Venter DP & Oliver W 2004 Receptor advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology. British Journal of Clinical Pharmacology 57 373-387.
4. Callahan MJ 2002 Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. Journal of Clinical Gastroenterology 35 (Suppl 1) 58-67.
5. Chabbert-Buffet N, Olivennes F & Bouchard P 2003 GnRH antagonists. Clinical Obstetrics and Gynecology 46 254-264.
6. Claude PA, Wotta DR, Zhang XH, Prather PL, McGinn TM, Erickson LJ, Loh HH & Law PY 1996 Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. PNAS 93 5715-5719.
7. Conn PM & Crowley F 1991 Gonadotropin-releasing hormone and its analogues. New England Journal of Medicine 324 93-103.
8. Conn PM, Janovick JA, Stanislaus D, Kuphal D & Jennes L 1995 Molecular and cellular bases of gonadotropin-releasing hormone action in the pituitary and central nervous system. Vitamins and Hormones 50 151-214.
9. Coy D, Hovart A & Nekola M 1982 Peptide antagonists of LH-RH: large increases of antiovulatory activities produced by basic D-amino acids in the six position. Endocrinology 110 1445-1447.
10. Cusan L, Auclair C, Belanger A, Ferland L, Kelly PA, Seguin C & Labrie F 1979 Inhibitory effects of long-term treatment with a LHRH agonist on the pituitary-gonadal axis in male and female rats. Endocrinology 104 1369-1376.
11. DeFazio J, Meldrum DR, Laufer L, Vale W, Rivier J, Lu JK & Judd HL 1983 Induction of hot flashes in premenopausal women treated with a long-acting GnRH agonist. Journal of Clinical Endocrinology and Metabolism 56 445-448.
12. Doggrell SA 2004 Telmisartan - killing two birds with one stone. Expert Opinion in Pharmacotherapy 11 2397-2400.
13. Emons G, Ortmann O, Schulz K-D & Schally AV 1997 Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends in Endocrinology and Metabolism 8 355-362.
14. Filicori M 1994 Gonadotrophin-releasing hormone agonists. A guide to use and selection. Drugs 48 41-58.
15. Fogelman I 1992 Gonadotropin-releasing hormone agonists and the skeleton. Fertility and Sterility 57 715-724.
16. Frolund B, Ebert B, Kristiansen U, Liljefors T & Krogsgaard-Larsen P 2002 GABA(A) receptor ligands and their therapeutic potentials. Current Topics in Medicinal Chemistry 8 817-832.
17. Gao ZG & Jacobson KA 2004 Partial agonists for A(3) adenosine receptors. Current Topics in Medicinal Chemistry 4 855-862.
18. 1A angiotensin II receptor induces its constitutive activation. Journal of Biological Chemistry 272 1822-1826.
19. Han M, Lou J, Nakanishi K, Sakmar TP & Smith SO 1997 Partial agonist activity of 11-cis-retinal in rhodopsin mutants. Journal of Biological Chemistry 272 23081-23085.
20. Horvath J E, Toller GL, Schally AV, Bajo AM & Groot K 2004 Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. PNAS 101, 4996-5001.
21. Huckle WR & Conn PM 1987 The use of lithium in measurement of stimulated pituitary inositol phospholipid turnover. Methods in Enzymology 141 149-155.
22. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, Aebi A, Aubert ML, Semple G, Robson P et al. 2001 GnRH antagonists: a new generation of long acting analogues incorporating urea functions at positions 5 and 6. Journal of Medicinal Chemistry 44 453-467.
23. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J & Christiansen C 1988 The effect of gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. Journal of Clinical Endocrinology and Metabolism 67 701-706.
24. Karten M J & Rivier JE 1986 GnRH analog design structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocrine Reviews 7 44-66.
25. Kiesel LA, Rody A, Greb RR & Szilágy A 2002 Clinical use of GnRH analogues. Clinical Endocrinology 56 677-687.
26. Knobil E 1974 On the control of gonadotropin secretion in the rhesus monkey. Recent Progress in Hormone Research 30 1-46.
27. Lieberman JA 2004 Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18 251-267.
28. Lipworth BJ & Grove A 1997 Evaluation of partial β-adrenoceptor agonist activity. British Journal of Clinical Pharmacology 43 9-14.
29. Matta WH, Shaw RW, Hesp R & Kats D 1987 Hypogonadism induced by luteinizing hormone releasing hormone agonist analogues: effect on bone density in premenopausal women. British Medical Journal 294 1523-1524.
30. Millar RP, Lu Z-L, Pawson AJ, Flanagan CA, Morgan K & Maudsley SR 2004 Gonadotropin-releasing hormone receptors. Endocrine Reviews 25 235-275.
31. Morin D, Cotte N, Balestre MN, Mouillac B, Manning M, Breton C & Barberis C 1998 The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. FEBS Letters 441 470-475.
32. 1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35 16435-16442.
33. Ortmann O, Weiss JM & Diedrich K 2002 Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reproductive BioMedicine Online 5 (Suppl 1) 1-7.
34. Pahwa GS, Kullander S, Vollmer G, Oberheuser F, Knuppen R, Emons G 1991 Specific low affinity binding sites for gonadotropin-releasing hormone in human endometrial carcinomata. European Journal of Obstetrics and Gynecology and Reproductive Biolology 41 135-142.
35. Pierce SJ, Gazvani R & Farguharson RG 2000 Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow up. Fertility and Sterility 74 964-968.
36. Pliska V 1999 Partial agonism: mechanisms based on ligand-receptor interactions and on stimulus-response coupling. Journal of Receptor and Signal Transduction Research 19 597-629.
37. Reynolds GP 2004 Receptor mechanisms in the treatment of schizophrenia. Journal of Psychopharmacology 18 340-345.
38. Rivier J, Varga J, Porter J, Perrin M, Haas Y, Corrigan A, Rivier C, Vale W, Struthers S & Hagler A 1986 Potent conformationally constrained analogs of GnRH. The Ninth American Peptide Symposium, Toronto, Canada, pp 541-544.
39. Rivier JE, Jiang G, Struthers RS, Koerber SC, Porter J, Cervini LA, Kirby DA, Craig AG & Rivier CL 2000a Design of potent dicyclic (1-5/ 4-10) gonadotropin releasing hormone (GnRH) antagonists. Journal of Medicinal Chemistry 43 807-818.
40. Rivier JE, Porter J, Cervini LA, Lahrichi SL, Kirby DA, Struthers RS, Koerber SC & Rivier CL 2000b Design of monocyclic (1-3) and dicyclic (1-3/4-10) gonadotropin releasing hormone (GnRH) antagonists. Journal of Medicinal Chemistry 43 797-806.
41. Rivier JE, Struthers RS, Porter J, Lahrichi SL, Jiang G, Cervini LA, Ibea M, Kirby DA, Koerber SC & Rivier CL 2000c Design of potent dicyclic (4-10/5-8) gonadotropin releasing hormone (GnRH) antagonists. Journal of Medicinal Chemistry 43 784-796.
42. Santen RJ & Bardin CW 1973 Episodic luteinizing hormone secretion in man: pulse analysis, clinical interpretation, and physiological mechanisms. Journal of Clinical Investigation 52 2617-2628.
43. Spivak CE, Beglan CL, Seidleck BK, Hirshbein LD, Blaschak CJ, Uhl GR & Surratt CK 1997 Naloxone activation of μ-opioid receptors mutated at a histidine residue lining the opioid binding cavity. Molecular Pharmacology 52 983-992.
44. Strader CD, Candelore MR, Hill WS, Dixon RA & Sigal IS 1989 A single amino acid substitution in the β-adrenergic receptor promotes partial agonist activity from antagonists. Journal of Biological Chemistry 264 16470-16477.
45. Sun Y-M, Flanagan CA, Illing N, Ott TR, Sellar R, Fromme BJ, Hapgood J, Sharp P, Seaflon SC & Millar RP 2001 A chicken gonadotropin-releasing hormone receptor that confers agonist activity to mammalian antagonists. Journal of Biological Chemistry 276 7754-7761.
46. Tummon IS, Ali A, Pepping ME, Radwanska E, Binor Z & Dmowski WP 1988 Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertility and Sterility 49 792-796.
47. Ulloa-Agairre A & Timossi C 2000 Biochemical and functional aspects of gonadotropin-releasing hormone and gonadotropins. Reproductive Biomedicine Online 1 48-62.
48. Vale W, Grant G, Rivier J, Monahan M, Amoss M, Blackwell R, Burgus R & Guillemin R 1972 Synthetic polypeptide antagonists of the hypothalamic luteinizing hormone releasing factor. Science 176 933-934.
49. Valove FM, Finch C, Anasti JN, Froehlich J & Flack MR 1994 Receptor binding and signal transduction are dissociable functions requiring different sites on follicle-stimulating hormone. Endocrinology 135 2657-2661.
50. 2A adrenergic receptors. British Journal of Pharmacology 126 939-948.